RankingsPricing
  1. US-listed companies
  2. Sonnet BioTherapeutics Holdings, Inc.

Sonnet BioTherapeutics Holdings, Inc.SONN

Market cap
$3.19M
P/E ratio
Back to summarized table
Income statementBalance sheetCash flow
Dec 31,
2013		Dec 31,
2014		Dec 31,
2015		Dec 31,
2016		Dec 31,
2017		Dec 31,
2018		Dec 31,
2019		Sep 30,
2020		Sep 30,
2021		Sep 30,
2022
Net loss-5,214,119-5,725,873-12,136,526-9,076,572-6,794,771-6,854,420-17,726,384-24,265,115-24,983,961-29,721,841
Acquired in-process research and development-------7-971,477
Depreciation---------12,845
Amortization of operating lease right-of-use asset---------80,412
Share-based compensation------126,829--876,368
Prepaid expenses and other current assets165,356-120,456-221,683-113,633-22,157-116,154152,588-901,7361
Other assets---------82,959-
Accounts payable---------971,041
Accrued expenses---------727,622
Operating lease liability---------82,060-83,685
Deferred income------42,840-215,061---349,943
Net cash used in operating activities-2,704,199-1,026,940-5,367,824-509,158-724,432575,218-4,046,550---27,687,278
Purchases of in-process research and development---------896,477
Purchases of property and equipment422122472,882---
Net cash used in investing activities--2,171,424----2,442,864678,669---896,477
Proceeds from sale of preferred stock and common stock warrants, net of issuance costs---257,175348,171----2
Proceeds from sale of common stock, net of issuance costs---------2
Net cash provided by financing activities-3---23--4
Net (decrease) increase in cash-----191,713-23,094---24,569,188
Change in operating lease right-of-use asset and liability due to amended lease---------0
Issuance of common stock on vesting of restricted stock units---------2
In-process research and development in accrued expenses---------75,000
Common stock issuance costs in accrued expenses---------80,940